|
SFRS14 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.20410015291839E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.634400E-01 |
| Stage1-vs-Stage3 |
6.588200E-02 |
| Stage1-vs-Stage4 |
4.633500E-02 |
| Stage2-vs-Stage3 |
3.092000E-02 |
| Stage2-vs-Stage4 |
1.731690E-02 |
| Stage3-vs-Stage4 |
6.083600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.91559999979307E-08 |
| Normal-vs-Asian |
1.75881531561117E-12 |
| Caucasian-vs-AfricanAmerican |
3.442600E-01 |
| Caucasian-vs-Asian |
4.142600E-01 |
| AfricanAmerican-vs-Asian |
7.517400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.290600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
2.22019999999157E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.651000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.129200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.376400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.879000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.900800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.005200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.50119996830978E-09 |
| Classical-VS-Follicular |
5.697900E-03 |
| Classical-VS-Other |
4.970800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.98500113515843E-11 |
| Tall-VS-Other |
3.838200E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.433430E-01 |
| Follicular-VS-Normal |
4.62240246079659E-11 |
| Other-VS-Normal |
1.53775999999217E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
5.238200E-02 |
|
|
